Kenvue (NYSE:KVUE) Earns Neutral Rating from Analysts at Redburn Atlantic

Redburn Atlantic started coverage on shares of Kenvue (NYSE:KVUE - Free Report) in a research report report published on Thursday morning, MarketBeat.com reports. The firm issued a neutral rating and a $23.50 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Finally, Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and an average price target of $24.42.

Remove Ads

Kenvue Stock Performance

KVUE traded up $0.13 on Thursday, reaching $22.84. The company had a trading volume of 8,164,201 shares, compared to its average volume of 16,883,686. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $43.65 billion, a PE ratio of 43.09, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a 50-day moving average price of $22.69 and a 200-day moving average price of $22.40.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Grove Bank & Trust boosted its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. boosted its holdings in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its stake in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.